(Q39408906)

English

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 5 September 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

phase III clinical trial

0 references

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

William W Busse

8

object named as

William W Busse

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Eugene R Bleecker

2

object named as

Eugene R Bleecker

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

J Mark FitzGerald

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Parameswaran Nair

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Stephanie Korn

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ken Ohta

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Marek Lommatzsch

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Gary T Ferguson

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Peter Barker

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Stephanie Sproule

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Geoffrey Gilmartin

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Viktoria Werkström

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Magnus Aurivillius

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mitchell Goldman

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

CALIMA study investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

5 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

388

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

10056

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2128-2141

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Global asthma prevalence in adults: findings from the cross-sectional world health survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab in refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of loss of asthma control induced by corticosteroid withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between airways inflammation and asthma severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab: a unique IL-5 inhibitor for severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for Poorly Controlled, Eosinophilic Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring asthma control. Clinic questionnaire or daily diary?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931322-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)31322-8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39408906&oldid=1826324918"